News
FDA Suspends U.S. License of Chikungunya Vaccine
By Stephanie Brown HealthDay ReporterMONDAY, Aug. 25, 2025 (HealthDay News) -- The U.S. Food and Drug Administration is suspending the biologics license for the live-attenuated chikungunya vaccine, Ixchiq, in the United States. The move comes after reports of serious side effects in older adults similar to the symptoms of chikungunya virus.
FDA suspends license for chikungunya vaccine Ixchiq over serious safety concerns
The US Food and Drug Administration (FDA) announced late last week that it has suspended the license for French drugmaker Valneva's chikungunya vaccine, saying that continued administration of the vaccine to the public would pose a danger to health.
In a U-turn from a decision two weeks ago, the FDA – citing new safety events – said the vaccine is a ‘danger to health’.
Dr. Vinay Prasad, an oncologist who was a fierce critic of COVID vaccine and mask mandates, was appointed in May.
Dr. Vinay Prasad had been serving as the FDA's director of the Center for Biologics Evaluation and Research since May, and ...
Health and Me on MSN14h
Chikungunya Vaccine License Suspended In U.S. By FDA
The U.S. FDA has suspended the license for Valneva’s chikungunya vaccine Ixchiq after reports of severe side effects, ...
Thinking about what to do with your Pfizer shares? You are definitely not alone, especially as sentiment around the stock ...
IFLScience on MSN6d
COVID-19 “Vaccine Alternative” Injection Could Be On Fast-Track To Approval From FDA
Pharma company Invivyd, Inc. just announced it is working with the US Food and Drug Administration (FDA) on a pathway to ...
As a summer COVID-19 surge hits Michigan, unanswered questions abound about eligibility, insurance coverage and when new ...
Kids are back in school and that means flu season is right around the corner - but now, families have the option to give ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback